Pramlintide Reference

Plain English

What it is

Pramlintide is a lab-made copy of amylin, a natural hormone the pancreas releases to help control blood sugar after eating. It is an FDA-approved prescription medicine sold under the brand name Symlin.

What people use it for

Doctors prescribe it as a mealtime add-on for people with type 1 or type 2 diabetes who already use insulin at meals but still cannot keep their blood sugar in range. Even though some people online frame it as a weight-loss drug, it is not a stand-alone weight-loss product.

What the science shows

In a year-long, high-quality randomized trial in people with type 1 diabetes, adding pramlintide to insulin produced small improvements in long-term blood sugar control and a small drop in body weight, while the placebo group gained a little weight. This is human evidence, but the weight effect was modest.

The catch

It carries the FDA's strongest (boxed) warning: used together with insulin, it can cause severe low blood sugar, usually within a few hours of an injection. The most common side effects are nausea, vomiting, loss of appetite, and headache. It is a prescription medicine handled with a prescriber's oversight, not a casual weight-loss option.

Reference summary

Pramlintide is a label-verified synthetic amylin analog and the precursor product that informed Novo Nordisk's long-acting amylin development (cagrilintide and CagriSema). The Ratner 2004 Diabet Med long-term RCT (PMID 15498087) demonstrated improvements in HbA1c and weight in type 1 diabetes patients on insulin when pramlintide was added as a mealtime adjunct. The label-verified mealtime regimens for T1DM (15 to 60 mcg) and T2DM (60 to 120 mcg) are the routine clinical reference.

Regulatory and posture

Categories

Hormonal, Metabolic

Aliases

Symlin, Synthetic amylin analog (the precursor to long-acting cagrilintide)

Evidence posture

human

Regulatory status

FDA-approved prescription medication (Symlin, 2005). Indicated as an adjunct mealtime therapy in patients with type 1 or type 2 diabetes who use mealtime insulin and have failed to achieve glycemic control. Boxed warning for severe insulin-induced hypoglycemia.

Content review status

label verified

Related tools

• Injection-site rotation overview - Public overview of the Pro site-rotation planner.